IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. announced initial topline data confirming that Zimura® met its prespecified primary endpoint in its Phase 2b clinical trial.